Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202502053 A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (UMBRIEL) New Drug Phase Ⅱ
N202503006 Evaluation of the effectiveness and accuracy of mask rapid screening based on aptamers of MPT64, H37Ra and ManLAM antigens for the detection of Mycobacterium tuberculosis New Drug Phase Ⅲ
N202503021 A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function after Kidney Transplantation New Drug Phase Ⅲ
N202503077 A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016, an Allogeneic Anti-EGFR Conjugated Gamma Delta T cell (gdT) Therapy in Adult Subjects with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) New Drug Phase Ⅲ
N202503085 A pilot study to evaluate diagnostic yield rate of InheriNext in children with developmental delay/intellectual disability (DD/ID) by prioritization of pathogenic variants using both whole-exome sequencing and phenotyping data New Drug Phase Ⅱ
N202503086 A randomized, Phase 2, double-blind, placebo-controlled, parallel-group, 2-arm study to investigate the efficacy, safety, and tolerability of subcutaneous lunsekimig (SAR443765) in adult participants with high-risk asthma who are not currently eligible for biologic treatment. New Drug Phase Ⅱ
N202503121 A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants with Sjögren’s Syndrome (SS) New Drug Phase Ⅲ
N202504015 A Phase I Open-Label Study to Assess the Safety and Tolerability of Allogenic Human Umbilical Mesenchymal Stem Cell Therapy for Patients with Idiopathic Parkinson's Disease New Drug Phase Ⅲ
N202504046 A preliminary bioequivalence study to compare two ropinirole HCl PR tablets in healthy subjects under fed state. New Drug Phase Ⅲ
N202504048 A handheld fluorescence-imaging stick for detecting dental plague in patients with periodontitis New Drug Phase Ⅰ
1 2 3 4 5 6 7 8 9 10 31 32 / 32

TOP